Mercedes Delgado-Garcia

Mercedes Delgado-Garcia

Auto-generated profile, based on publicly available information

Mercedes Delgado-Garcia

Hospital Universitario Virgen del Rocío

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MDMercedes Delgado-García
Mercedes Delgado-García
BWBirgit Weynand
Birgit Weynand
LGLourdes Gómez-Izquierdo
Lourdes Gómez-Izquierdo
MHMaría José Hernández
María José Hernández
ÁBÁngela María Blanco
Ángela María Blanco
MBMichele Biscuola
Michele Biscuola
Background: Detection of epidermal growth factor receptor (EGFR)mutations in exons 18–21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors inEGFR-mutated patients. Therefore, choosing a suitable technique to testEGFRmutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material.The Idylla™EGFRMutation Test is a simple, fast and reliable method designed for the detection ofEGFRmutations from formalin-fixed paraffin-embedded samples.The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System.Methods: EGFRmutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen®EGFRRGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla).Results: The overall agreement between results obtained with the Idylla™EGFRMutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%.Conclusions: The Idylla™EGFRMutation Test passed its clinical validity performance characteristics for accuracy.

12 November 2014 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
MDMercedes Delgado-García
Mercedes Delgado-García
FMFuencisla Matesanz
Fuencisla Matesanz
AAAntonio Alcina
Antonio Alcina
MFMaría Fedetz
María Fedetz
MSMaria Isabel Garcia Sanchez
Maria Isabel Garcia Sanchez
MLMiguel Lucas
Miguel Lucas
Background: Recent findings have shown a correlation between the intrathecal IgG index and variants at the immunoglobulin heavy chain (IGHC) locus in patients with multiple sclerosis (MS). Objectives: The objective of this paper is to analyse the association of the locus with MS susceptibility and its relationship with intrathecal immunoglobulin (Ig) parameters. Methods: We genotyped the rs11621145 variant, located at the IGHC locus, in 2726 patients with MS and 2133 healthy controls. Associations of intrathecal IgG and IgM indexes with rs11621145 were analysed by linear regression analysis in 538 MS patients. Results: We found that rs11621145 showed statistically significant evidence for association with susceptibility to MS (odds ratio = 0.69, p = 1.053E-09), though validation of this result in additional cohorts would be desirable. We confirmed the association between the IgG index and the rs11621145 ( p = 6.85E-07, Beta = 0.207). Furthermore, rs11621145 was inversely correlated with IgM index ( p = 7.24E-04, Beta = -0.277), and therefore marks a decreased likelihood of presenting IgM oligoclonal bands (odds ratio = 0.38, p = 2.35E-06). Conclusions: Our results suggest that the polymorphism of the IGHC locus could be altering the switching of the Ig isotype in B cells and it may be interfering with T-dependent and T-independent antibody responses.

20 August 2019 in Research Square
Verified
Preprint
Open access
MDMercedes Delgado-Garcia
Mercedes Delgado-Garcia
BWBirgit Weynand
Birgit Weynand
LILourdes Gómez Izquierdo
Lourdes Gómez Izquierdo
MBMaría José Hernández Barrera
María José Hernández Barrera
ÁLÁngela María Blanco Lobo
Ángela María Blanco Lobo
MBMichele Biscuola
Michele Biscuola
BackgroundDetection of epidermal growth factor receptor ( EGFR) mutations in exons 18-21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy tyrosine kinase inhibitors in EGFR -mutated patients. Therefore, choosing a suitable technique for testing EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material. The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded sample. The aim of this study was the evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System conducting a Clinical Performance Evaluation.MethodsEGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen ® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla)ResultsThe overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%.ConclusionsThe Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.

28 February 2020 in Research Square
Verified
Preprint
Open access
PDF file
MDMercedes Delgado-Garcia
Mercedes Delgado-Garcia
BWBirgit Weynand
Birgit Weynand
LILourdes Gómez Izquierdo
Lourdes Gómez Izquierdo
MBMaría José Hernández Barrera
María José Hernández Barrera
ÁLÁngela María Blanco Lobo
Ángela María Blanco Lobo
MBMichele Biscuola
Michele Biscuola
Background detection of epidermal growth factor receptor ( EGFR) mutations in exons 18-21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material. The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System. Methods EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen ® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla). Results the overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions the Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.

7 February 2020 in Research Square
Verified
Preprint
Open access
PDF file
MDMercedes Delgado-Garcia
Mercedes Delgado-Garcia
BWBirgit Weynand
Birgit Weynand
LILourdes Gómez Izquierdo
Lourdes Gómez Izquierdo
MBMaría José Hernández Barrera
María José Hernández Barrera
ÁLÁngela María Blanco Lobo
Ángela María Blanco Lobo
MBMichele Biscuola
Michele Biscuola
Background: detection of epidermal growth factor receptor (EGFR) mutations in exons 18-21 is recommended in all patients with advanced Non-small-cell lung carcinoma due to the demonstrated efficiency of the standard therapy with tyrosine kinase inhibitors in EGFR-mutated patients. Therefore, choosing a suitable technique to test EGFR mutational status is crucial to warrant a valid result in a short turnaround time using the lowest possible amount of tissue material.The Idylla™ EGFR Mutation Test is a simple, fast and reliable method designed for the detection of EGFR mutations from formalin-fixed paraffin-embedded samples. The aim of this study was the Clinical Performace Evaluation of the Idylla™ EGFR Mutation Test on the Idylla™ System.Methods: EGFR mutational status was determined on 132 archived formalin-fixed paraffin-embedded tissue sections with Idylla™ technology. Results were compared with the results previously obtained by routine method in the reference lab (Therascreen® EGFR RGQ PCR v2, Qiagen in Molecular Pathology lab, Hospital Universitario Virgen del Rocío de Sevilla).Results: the overall agreement between results obtained with the Idylla™ EGFR Mutation Test and the Comparator test method was 95.38% (with 1-sided 95% lower limit of 91.7%) showing Positive Diagnostic Agreement of 93.22% and Negative Diagnostic Agreement of 97.18%, with a Limit Of Detection ≤5%. Conclusions: the Idylla™ EGFR Mutation Test passed its clinical validity performance characteristics for accuracy.